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Abstract: BACKGROUND Autosomal recessive polycystic kidney disease (ARPKD) shows a great phe-
notypic variability between patients, ranging from perinatal demise to mildly affected adults. Autosomal
dominant polycystic liver disease (PCLD) does not manifest in childhood. CASE-DIAGNOSIS/TREATMENT
A boy was reported with the co-occurrence of ARPKD and PCLD. He presented at the age of 16 days with
pyelonephritis and urosepsis. Subsequent investigations showed enlarged kidneys and hyperechogenic re-
nal medulla and liver parenchyma. Genetic analysis revealed compound heterozygous mutations in the
PKHD1 gene (p.Arg496X and p.Ser1862Leu). After his mother was diagnosed with PCLD, the finding
of a liver cyst on ultrasound prompted analysis of the PRKCSH gene, revealing a missense mutation
(p.Arg139His). At the most recent follow-up at 13 years of age, the patient’s course and clinical ex-
amination was uneventful with normal renal and liver function without evidence of portal hypertension.
CONCLUSIONS The patient with ARPKD and PCLD has so far demonstrated a benign clinical outcome,
consistent with the great phenotypic variability of ARPKD and, apart from the liver cyst, asymptomatic
manifestation of PCLD in childhood. However, close long-term follow-up is mandatory.
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Abstract
Background Autosomal recessive polycystic kidney disease
(ARPKD) shows a great phenotypic variability between
patients, ranging from perinatal demise to mildly affected
adults. Autosomal dominant polycystic liver disease
(PCLD) does not manifest in childhood.
Case-Diagnosis/Treatment A boy was reported with the
co-occurrence of ARPKD and PCLD. He presented at the age
of 16 days with pyelonephritis and urosepsis. Subsequent
investigations showed enlarged kidneys and hyperechogenic
renal medulla and liver parenchyma. Genetic analysis
revealed compound heterozygous mutations in the PKHD1
gene (p.Arg496X and p.Ser1862Leu). After his mother was
diagnosed with PCLD, the finding of a liver cyst on ultra-
sound prompted analysis of the PRKCSH gene, revealing a
missense mutation (p.Arg139His). At the most recent follow-
up at 13 years of age, the patient’s course and clinical
examination was uneventful with normal renal and liver
function without evidence of portal hypertension.
Conclusions The patient with ARPKD and PCLD has so far
demonstrated a benign clinical outcome, consistent with the
great phenotypic variability of ARPKD and, apart from the
liver cyst, asymptomatic manifestation of PCLD in child-
hood. However, close long-term follow-up is mandatory.
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Introduction
Autosomal recessive polycystic kidney disease (ARPKD) is
caused by mutations in the PKHD1 gene on chromosome
6p12. There is great phenotypic variability between fami-
lies, but also within families, ranging from perinatal demise
to mildly affected young adults [1, 2]. Patients with ARPKD
have hepatic fibrosis with dilated intrahepatic bile ducts, but
only rarely develop large liver cysts. Autosomal dominant
polycystic liver disease (PCLD) is caused by heterozygous
mutations in the PRKCSH gene (protein kinase C substrate
80 K-H) on chromosome 19p13 [3] or the SEC63 gene
(SEC63 homolog, S. cerevisiae) on chromosome 6q21 [4].
Mutations in these two genes explain about 20–25% of the
cases, indicating that at least one other locus is involved in
PCLD pathogenesis [5]. PCLD does not manifest in child-
hood, as liver cysts and clinical symptoms only develop
later in adulthood.
ARPKD, PLCD, and autosomal dominant polycystic
kidney disease (ADPKD) among others, belong to the group





Institute of Medical Genetics, University Zurich,
Zurich, Switzerland
C. Bergmann
Center for Human Genetics, Bioscientia,
Ingelheim, Germany
C. Bergmann
Department of Human Genetics, RWTH Aachen University,
Aachen, Germany
J. P. H. Drenth
Department of Gastroenterology and Hepatology,
Department of Medicine,
Radboud University Nijmegen Medical Center,
Nijmegen, The Netherlands
Pediatr Nephrol (2012) 27:1197–1200
DOI 10.1007/s00467-012-2137-5
of ciliopathy diseases. Fibrocystin/polyductin and
polycystin-1/2, the products of the genes responsible for
ARPKD and ADPKD, are integral membrane proteins in
the cilia membrane, whereas glucosidase IIβ and Sec63p,
the products of the PRKCSH and SEC63 genes, function in
post-translational translocation of proteins into the endo-
plasmatic reticulum. This case describes the first reported
pediatric patient with co-occurrence of ARPKD and PCLD.
Case report
The boy was born prematurely after an uneventful pregnan-
cy at 36 5/7 weeks gestation. He was the only child of non-
consanguineous Finnish parents. Birth weight was 2,800
grams and the neonatal course was normal. He presented
at the age of 16 days with pyelonephritis and urosepsis (E.
coli) with full recovery on antibiotic therapy for 14 days
(initially gentamicin/amoxicillin, followed by ceftriaxone).
Subsequent renal ultrasound showed mildly enlarged
kidneys (length 7.4 cm) and hyperechogenic medulla. A
micturition cystography demonstrated normal bladder and
urethra, excluding vesicoureteric reflux. The further clinical
course was uneventful. Ultrasound at the regularly planned
follow-up at 9 months of age demonstrated hyperechogenic
renal medulla suggestive of nephrocalcinosis and hypere-
chogenic liver. Renal function, assessed as plasma creati-
nine, urinary calcium and oxalate excretion, and liver
function tests were all normal.
Repeated ultrasound at the age of 2 years showed en-
larged kidneys and persistent hyperechogenic renal medulla
and liver suggestive of ARPKD prompting further investi-
gations. Genetic analysis revealed compound heterozygous
mutations in the PKHD1 gene (maternally, c.1486C>T/p.
Arg496X; paternally: c.5585C>T/p.Ser1862Leu). Ultra-
sound of the father (at the age of 38 years) showed normal
kidneys and liver, whereas the mother’s ultrasound (at the
age of 37 years) showed normal kidneys, but an abnormal
liver (see below). Thus, a diagnosis of ARPKD was made in
the boy. Autosomal dominant polycystic kidney disease
(ADPKD) appeared to be unlikely as renal parental ultra-
sound was normal and family history for renal disease was
negative. However, as about 2% of ADPKD cases are due to
de novo mutations (which were not tested), ADPKD could
not be formally ruled out.
When the boy was 7 years old, his mother was diagnosed
(at the age of 40 years) with an aneurysm of the anterior
cerebral artery, which was successfully clipped. Subsequent
investigations showed multiple liver cysts, but again normal
renal ultrasound and renal function. Family history revealed
that the maternal grandmother also had liver cysts. The
suggested diagnosis of PCLD was confirmed by genetic
analysis showing a missense mutation in exon 6 of the
PRKCSH gene (c.416G>A; p.Arg139His) [6]. The mother
died at the age of 45 years of septicemia.
The boy’s further course was uneventful with normal
somatic and cognitive development. Repeated ultrasound
showed persistent hyperechogenicity of both the renal
medulla and the liver. At the age of 9 years, a small
cyst was detected in the liver segment IV (Fig. 1), sug-
gestive of PCLD. Genetic analysis of the PRKCSH gene
showed the maternal mutation, confirming the diagnosis
of PCLD.
At the most recent follow-up at the age of 13 years, the
boy was—apart from seasonal allergic pollinosis—asymp-
tomatic. His clinical examination was uneventful. Renal and
liver function, full blood count, urinalysis, and blood pres-
sure were normal. In addition, echocardiography and cere-
bral MRI—performed to detect mitral valve prolapse or
cerebral aneurysm—showed normal findings. Ultrasound
of the liver and kidneys demonstrated persistent hyperecho-
genicity of the liver and renal medulla and normal-sized
right (length 9.5 cm), but enlarged left kidney (10.5 cm). There
was no evidence of portal hypertension or splenomegaly. So
far, the patient has not been given any medication.
Discussion
This report describes a male patient with the combination of
two rare diseases, ARPKD and PCLD, genetic analysis
confirming the clinical diagnosis. Ultrasound findings of
Fig. 1 Sonography of the liver at the age of 9 years. A small cyst
adjacent to hepatic vessels (located in segment IV); parenchyma with
slightly hyperechogenic and nodular structure
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kidneys and liver were consistent with ARPKD, but no liver
biopsy was performed to verify hepatic fibrosis. There
should be little doubt about the pathogenicity of the two
mutations in the PKHD1 gene (c.1486C>T/p.Arg496X and
c.5585C>T/p.Ser1862Leu). The truncating change on the
maternal allele represents the most frequent Finnish PKHD1
founder mutation. The missense mutation detected on the
paternal allele was not present in 400 control chromosomes,
affects an evolutionarily conserved amino acid and was
predicted in silico by different bioinformatic tools used
(AlignGVGD, SIFT, PolyPhen2, and PMut) to be of patho-
genic relevance.
Repeated ultrasound revealed a liver cyst at young age
(9 years), unusual for both ARPKD and PCLD as cysts in
PCLD usually only develop in adulthood. However, it can
not be ruled out that the cystic structure might mimic a
dilated hepatic duct as in ARPKD.
The main clinical issue for this child with co-
occurrence of both ARPKD and PCLD is the concern
that the combination will lead to earlier clinical presen-
tation and poor(er) outcome. Whereas ARPKD carries
substantial morbidity and mortality among infants and
children, PCLD is asymptomatic during childhood. So
far, the patient’s clinical course with ARPKD and PCLD
has been—apart from the neonatal urosepsis—uneventful.
Extensive investigations, including repeated assessments
of renal and liver function, echocardiography, and cere-
bral MRI, were normal.
ARPKD is caused by mutations in the PKHD1 gene and
occurs with a proposed incidence of 1:20,000 [1]. Principal
histologic manifestations involve both the kidneys and the
liver, with dilation of renal collecting ducts and distal tubuli
as well as dysgenesis of the hepatic portal triad known as
ductal plate malformation. Renal ultrasound shows enlarged
kidneys with hyperechogenic parenchyma and small cysts.
The hepatobiliary findings include hyperechogenic liver
parenchyma and dilated intrahepatic bile ducts (Caroli syn-
drome), but usually no large liver cysts. There is great
phenotypic variability between families, but also within
families, ranging from perinatal demise to mildly affected
adults [1, 2]. The 1- and 10-year survival rates are 85 and
82%, respectively. Chronic renal failure is first detected at a
mean of 4 years, and renal survival rates (defined as start of
renal replacement therapy or death due to end-stage renal
failure) are 86, 71, and 42% at 5, 10, and 20 years, respec-
tively [1]. Sequelae of congenital hepatic fibrosis and portal
hypertension occur in almost half of patients. A positive
correlation can be demonstrated between renal and hepato-
biliary morbidity [1].
Fibropolycystic liver diseases in children include hepatic
fibrosis/ARPKD as well as biliary hamartoma, choledochal
cysts and PCLD [7]. Autosomal dominant PCLD is a
distinct entity of cotranslational protein processing [8]
caused by a mutation in either the PRKCSH gene [3] or
the SEC63 gene [4], with a prevalence of 1:150,000. The
cysts probably arise from biliary microhamartomas and have
no connection to the biliary tree. Liver structure is un-
changed, and hepatic fibrosis is absent in liver biopsy speci-
mens or explanted livers [9]. Liver function remains normal
in most patients and kidney function is not affected. PCLD
is generally a mild disease and symptoms develop only later
in adulthood, mainly due to increased intra-abdominal pres-
sure caused by large liver cysts. Usually, women tend to
present more and larger cysts than men. Mitral valve abnor-
malities are common (20%); some patients have inguinal
hernia, colonic diverticula, and gallstones, whereas only a
few develop cerebral aneurysms (4%) [10].
A further cause of liver cysts in adults is ADPKD.
The occurrence of liver cysts is related to renal function
and age: the majority of patients above 40 years of age
have liver cysts on ultrasound, in contrast to none below
10 years [11].
ARPKD, ADPKD, and PCLD are ciliopathies. Thus,
questions arise as to whether ARPKD and PCLD share a
common pathway and whether their co-occurrence might
lead to earlier development of cysts and poorer clinical
outcome. In fact, Fedeles et al. have recently shown a
genetic interaction network of five genes for human poly-
cystic kidney and liver diseases in mice [12]. The genes
PRKCSH and SEC63 and their respective gene products
glucosidase IIβ and Sec63p function in protein translocation
and quality control pathways in the endoplasmatic reticu-
lum. Glucosidase IIβ and Sec63p are required for adequate
expression of a functional complex of the ADPKD gene
products polycystin-1 and polycystin-2, with polycystin-1
being the rate-limiting component. In addition, fibrocystin/
polyductin (the product of the gene PKHD1) is an endo-
plasmatic reticulum-passing transmembrane protein, thus a
client protein for glucosidase IIβ and Sec63p. Fedeles et al.
have shown that inactivation of SEC63 in mice with
ARPKD led to more severe cystic disease. Their interpreta-
tion was that co-occurrence of PCLD and ARPKD led to
reduced dosage of polycystin-1, which sensitized kidney
tubules and bile ducts to expression of more severe cystic
phenotypes resulting from alterations in fibrocystin/poly-
ductin [12].
These data suggest that patients with co-occurrence of
ARPKD and PLCD are at risk of earlier development of
both kidney and liver cysts with subsequent poorer out-
come. However, the observation of the long-term course of
our patient suggests a discordant clinical pattern with a mild
renal phenotype of ARPKD and an early occurrence of a
liver cyst in PCLD. Thus, close long-term follow-up is
mandatory.
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